Ovoca Bio (CDI) (OVB) RNS Announcements

Add to Alert list
Date Time Source Announcement
04 Nov 2021 03:46 PM
RNS
Board Change
14 Sep 2021 07:00 AM
RNS
Interim Results
29 Jul 2021 05:00 PM
RNS
Result of AGM
24 Jun 2021 07:00 AM
RNS
Annual Report and Notice of AGM
10 Mar 2021 07:00 AM
RNS
Migration of Participating Securities
16 Feb 2021 02:00 PM
RNS
Result of EGM
29 Jan 2021 07:00 AM
RNS
First Patient Enrolled in Phase II Study - BP-101
25 Jan 2021 03:30 PM
RNS
Notice of EGM
05 Jan 2021 07:00 AM
RNS
Re-Filing of Marketing Authorisation Application
17 Dec 2020 02:45 PM
RNS
Result of AGM
27 Nov 2020 03:08 PM
RNS
Notice of AGM
09 Oct 2020 07:00 AM
RNS
Appointment of Chief Business Officer
02 Oct 2020 11:06 AM
RNS
Second Price Monitoring Extn
02 Oct 2020 11:00 AM
RNS
Price Monitoring Extension
02 Oct 2020 09:05 AM
RNS
Second Price Monitoring Extn
02 Oct 2020 09:00 AM
RNS
Price Monitoring Extension
02 Oct 2020 07:00 AM
RNS
Update re Russian Marketing Authorisation
28 Sep 2020 07:00 AM
RNS
Death of a Director
21 Sep 2020 07:00 AM
RNS
Interim Results
14 Aug 2020 11:05 AM
RNS
Second Price Monitoring Extn
14 Aug 2020 11:00 AM
RNS
Price Monitoring Extension
26 Jun 2020 07:00 AM
RNS
Annual Report
14 Apr 2020 02:05 PM
RNS
Second Price Monitoring Extn
14 Apr 2020 02:00 PM
RNS
Price Monitoring Extension
24 Mar 2020 07:00 AM
RNS
Acquisition of Remaining Minority Interest in IVIX
07 Nov 2019 12:45 PM
RNS
Attendance at Bio-Europe Conference
16 Sep 2019 07:00 AM
RNS
Interim Results
12 Sep 2019 07:00 AM
RNS
Filing of Marketing Authorisation Application
28 Aug 2019 07:00 AM
RNS
Directorate Change
08 Aug 2019 04:14 PM
RNS
Result of AGM
08 Aug 2019 09:05 AM
RNS
Second Price Monitoring Extn
08 Aug 2019 09:00 AM
RNS
Price Monitoring Extension
08 Aug 2019 07:00 AM
RNS
AGM Statement
26 Jul 2019 07:00 AM
RNS
Directorate Change
25 Jul 2019 04:41 PM
RNS
Second Price Monitoring Extn
25 Jul 2019 04:35 PM
RNS
Price Monitoring Extension
28 Jun 2019 07:00 AM
RNS
Annual Report and Notice of AGM
23 Apr 2019 07:00 AM
RNS
US and EU Clinical Development Plans
29 Mar 2019 07:00 AM
RNS
Director/PDMR Shareholding
27 Mar 2019 07:00 AM
RNS
Operational Update & Additional Investment in IVIX
25 Mar 2019 07:00 AM
RNS
Primary Endpoints Met in Libicore Phase III Study
31 Dec 2018 07:00 AM
RNS
Director/PDMR Shareholding
28 Sep 2018 07:00 AM
RNS
Interim Results
26 Sep 2018 07:00 AM
RNS
Completion of Acquisition of IVIX
03 Aug 2018 07:00 AM
RNS
Change of Name to Ovoca Bio plc
30 Jul 2018 08:05 AM
RNS
Readmission to trading on AIM and ESM
27 Jul 2018 02:40 PM
RNS
Results of Meetings
04 Jul 2018 10:00 AM
RNS
ESM - Schedule One
04 Jul 2018 07:00 AM
RNS
Proposed Acquisition of IVIX
25 May 2018 07:00 AM
RNS
Publication of Annual Report

Ovoca Bio PLC is a biopharmaceutical company focused on women's health, specifically developing novel treatments for female sexual dysfunction. Their lead product, Orenetide (BP-101), is a synthetic peptide administered via nasal spray, designed to treat hypoactive sexual desire disorder in premenopausal women. The company is incorporated in Ireland and operates in Ireland, the UK, and Russia. It is listed in London under the ticker OVB.

OVB share price was suspended from AIM on 7 May 2025.

 

UK 100

Latest directors dealings